Translating the metastasis paradigm from scientific theory to clinical oncology.
Cancer metastasis contributes to significant morbidity and mortality. Patients with metastatic cancer, often considered incurable, are provided with either supportive care or aggressive management without curative intent. Despite decades of research toward unraveling cancer progression mechanisms, the current body of knowledge has not translated into effective antimetastasis therapies, but recent findings challenge the classic notion that metastases develop during the late stages of carcinogenesis. Here, we evaluate the scientific evidence in the context of the multistage metastasis model. The resolution of current controversies has implications on both the prognostic value of molecular technology and the future of targeted therapies for the clinical benefit of metastasis patients.
Dong
Fei
F
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20902, USA.
Budhu
Anuradha S
AS
Wang
Xin Wei
XW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology / Q000378:metabolism; D008954:Models, Biological; D009362:Neoplasm Metastasis / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D000911:Antibodies, Monoclonal; D036341:Intercellular Signaling Peptides and Proteins